Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic
Study Details
Study Description
Brief Summary
This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying time.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Prevalence of infantile colic varies according to the definition used but estimates range between 5 % and 26 % of the infant population. To differentiate colic from other, more serious conditions it should be characterized by several clinical features. Infant colic is often accompanied by flushing the face, frown, tensing of the abdomen, clenching of the fists, and drawing up the leg, frequent, prolonged, and intense crying or fussiness in a healthy infant. Even though infant colic is benign and usually self-limiting condition it is a source of major distress for the infant, parents, family, and health care givers.
Despite infant colic occurs frequently, little agreement has been reached on the definition, pathogenesis, or the optimal management strategy for infant colic. Recent systematic reviews and meta-analyses showed that probiotic L. reuteri DSM 17938 supplementation significantly lowered the number of hours of crying and fussing daily. A significant peak effect was seen at 3 weeks in most studies. Interestingly, babies with infant colic were found to have increased evidence of gut inflammation, as evidenced by high levels of the antimicrobial peptide fecal calprotectin; also, the levels of fecal calprotectin declined significantly as the condition resolved.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: L. reuteri 5 drops administered once daily for 21 days |
Dietary Supplement: L. reuteri
Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
|
| Placebo Comparator: Placebo 5 drops administered once daily for 21 days |
Dietary Supplement: Placebo
Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
|
Outcome Measures
Primary Outcome Measures
- Crying and fussing time [From baseline to Day 7]
Change in daily crying and fussing time measured by Baby Day Diary
Secondary Outcome Measures
- Crying and fussing time [From baseline to Day 3, Day 14, Day 21]
Change in mean daily crying and fussing time measured by Baby Day Diary
- Crying time [From baseline to Day 3, Day 7, Day 14, Day 21]
Change in mean daily crying time measured by Baby Day Diary
- Number of responders [From baseline to Day 3, Day 7, Day 14, Day 21]
Proportion of responders defined as reduction of daily average crying time with 50 % compared to baseline
- Family quality of life (family QoL) [From baseline to Day 7 and Day 21]
Change in family QoL measured by the PedsQL Family Impact Module (Acute) - Total Score
- Sleeping time [From baseline to Day 3, Day 7, Day 14, Day 21]
Change in mean sleeping time measured by Baby Day Diary
- Maternal depression [From baseline to Day 7 and Day 21]
Change in maternal depression measured by the Edinburgh Postnatal Depression Scale Total Score
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged between 3-8 weeks at screening.
-
Gestational age 37 weeks - 41 weeks at birth.
-
Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.
-
No birth trauma and non-syndromic.
-
Exclusively or predominantly breastfed infants (> 50 % breast fed).
-
Willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.)
-
Readiness and the opportunity for parents to fill out a study diary, questionnaires.
-
Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents have to report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24 hour period should show 3 or more hours of crying/fussing time.
-
Parent/caregiver with ability to understand and comply with the requirements of the study, as judged by the Investigator.
-
Parent/caregiver willing and able to give informed consent for their and their infant's participation in the study.
-
The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 4 (Day 7), and Visit 6 (Day 21) and complete the study questionnaires.
-
Infant is considered healthy, following physical exam.
Exclusion criteria
-
Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).
-
Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents.
-
Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.
-
Infants with reported exposure to probiotics in the previous 8 weeks (since birth).
-
Infants with reported exposure to antibiotics in the previous 8 weeks (since birth).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Atlantia Clinical Trials | Cork | Ireland |
Sponsors and Collaborators
- BioGaia AB
- Atlantia Food Clinical Trials
Investigators
- Study Director: Jenny Palming, PhD, BioGaia AB
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CSUB0197